| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |

From the Department of Pathology and Molecular Medicine,* Centre for Gene Therapeutics, and the Hamilton Regional Laboratory Medicine Program,
McMaster University, Hamilton, Ontario, Canada
Endometriosis, the growth of ectopic endometrial tissue, is a chronic recurrent disease affecting 10% of the female population causing dyspareunia, pelvic pain, dysmenorrhea, and infertility. Suppression of ovarian activity is the cornerstone of medical therapy with limited benefit and severe adverse effects. Angiogenesis plays a major role in the development of endometriosis suggesting that anti-angiogenic therapy would offer a new therapeutic approach. We report successful treatment of endometriosis in estrogen-supplemented ovariectomized mice by transient overexpression (6 to 10 days of duration) of the gene for a natural angiogenesis inhibitor angiostatin, delivered to the peritoneum by a replication-deficient adenovirus vector (AdAngiostatin). Established endometriosis was eradicated in 14 of 14 AdAngiostatin-treated animals, whereas 11 of 13 control animals showed full disease development. Administered to normal cycling mice for the same transient period, AdAngiostatin caused impaired ovarian function with suppressed corpus luteum development, decreased production of estradiol and progesterone, decreased ovarian and uterine weight, and increased body weight. AdAngiostatin treatment lowered the levels of sex steroids but did not induce total castration. Gene therapy with angiogenic inhibitors is a highly effective treatment for endometriosis, even in a host with preserved estrogen levels. However, local or targeted delivery of the gene must be considered to avoid prolonged systemic effects and impaired ovarian function.
Related articles in Am J Pathol:
This article has been cited by other articles:
![]() |
S. Defrere, J.C. Lousse, R. Gonzalez-Ramos, S. Colette, J. Donnez, and A. Van Langendonckt Potential involvement of iron in the pathogenesis of peritoneal endometriosis Mol. Hum. Reprod., July 1, 2008; 14(7): 377 - 385. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Van Langendonckt, J. Donnez, S. Defrere, G. A.J. Dunselman, and P. G. Groothuis Antiangiogenic and vascular-disrupting agents in endometriosis: pitfalls and promises Mol. Hum. Reprod., May 1, 2008; 14(5): 259 - 268. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Fainaru, A. Adini, O. Benny, I. Adini, S. Short, L. Bazinet, K. Nakai, E. Pravda, M. D. Hornstein, R. J. D'Amato, et al. Dendritic cells support angiogenesis and promote lesion growth in a murine model of endometriosis FASEB J, February 1, 2008; 22(2): 522 - 529. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Van Langendonckt, C. Punyadeera, R. Kamps, G. Dunselman, L. Klein-Hitpass, L.J. Schurgers, J. Squifflet, J. Donnez, and P. Groothuis Identification of novel antigens in blood vessels in rectovaginal endometriosis Mol. Hum. Reprod., December 1, 2007; 13(12): 875 - 886. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. W. Laschke and M. D. Menger In vitro and in vivo approaches to study angiogenesis in the pathophysiology and therapy of endometriosis Hum. Reprod. Update, July 1, 2007; 13(4): 331 - 342. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Oktem, I. Esinler, D. Eroglu, N. Haberal, N. Bayraktar, and H. B. Zeyneloglu High-dose atorvastatin causes regression of endometriotic implants: a rat model Hum. Reprod., May 1, 2007; 22(5): 1474 - 1480. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Masuda, T. Maruyama, E. Hiratsu, J. Yamane, A. Iwanami, T. Nagashima, M. Ono, H. Miyoshi, H. J. Okano, M. Ito, et al. Noninvasive and real-time assessment of reconstructed functional human endometrium in NOD/SCID/{gamma}Formula immunodeficient mice PNAS, February 6, 2007; 104(6): 1925 - 1930. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M. Becker, R. D. Wright, R. Satchi-Fainaro, T. Funakoshi, J. Folkman, A. L. Kung, and R. J. D'Amato A Novel Noninvasive Model of Endometriosis for Monitoring the Efficacy of Antiangiogenic Therapy Am. J. Pathol., June 1, 2006; 168(6): 2074 - 2084. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Defrere, A. Van Langendonckt, R. G. Ramos, M. Jouret, M. Mettlen, and J. Donnez Quantification of endometriotic lesions in a murine model by fluorimetric and morphometric analyses Hum. Reprod., March 1, 2006; 21(3): 810 - 817. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. A. Solovjov, E. Pluskota, and E. F. Plow Distinct Roles for the {alpha} and {beta} Subunits in the Functions of Integrin {alpha}M{beta}2 J. Biol. Chem., January 14, 2005; 280(2): 1336 - 1345. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Varma, T. Rollason, J. K Gupta, and E. R Maher Endometriosis and the neoplastic process Reproduction, March 1, 2004; 127(3): 293 - 304. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Suzumori, M. Sugiura-Ogasawara, K. Katano, and K. Suzumori Women with endometriosis have increased levels of placental growth factor in the peritoneal fluid compared with women with cystadenomas Hum. Reprod., December 1, 2003; 18(12): 2595 - 2598. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |